TP53 and head and neck squamous cell carcinoma: In addition, TP53 mutations are more likely to occur in HPV-negative HNSCC and less common in HPV-positive HNSCC (Helman et al., 2014), possibly suggesting that TP53 acts as an indicator of radiotherapy sensitization target and HPV typing in patients with HNSCC, which has great value for clinical studies.